-

Shareholder Alert: Robbins LLP Announces That Cabot Oil and Gas Corporation (COG) is Being Sued for Misleading Shareholders

SAN DIEGO & HOUSTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that on October 5, 2020, a purchaser of Cabot Oil and Gas Corporation (NYSE: COG) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between October 23, 2015 and June 12, 2020. Cabot is an independent oil and gas company primarily operating in Pennsylvania's Marcellus Shale.

If you have suffered a loss due to Cabot Oil and Gas Corporation's misconduct, click here.

Cabot Oil and Gas Corporation (COG) Sued for Faulty Gas Wells and Water Pollution

According to the complaint, Cabot failed to disclose and made misleading statements surrounding the company's inadequate environmental controls and procedures, including its failure to fix faulty gas wells resulting in the pollution of local PA water supplies. Cabot consistently downplayed the potential civil and criminal liabilities that could result, despite the likelihood that these accusations would lead to serious governmental scrutiny and financial harm. On July 26, 2019, Cabot filed a Form 10-Q for the quarter ending June 30, 2019, disclosing that the company had received two notices of violation from the PA Department of Environmental Protection in June and November of 2017, for failing to prevent the migration of gas into local fresh groundwater sources. On this news, Cabot's shares fell 12.07% the same day. Then, on June 15, 2020, following a grand jury investigation, the PA attorney general's office charged Cabot with fifteen criminal counts related to the company's failure to fix faulty gas wells and the resulting water pollution. On this news, Cabot's shares fell 3.34%, closing at $19.40 per share on June 15, 2020.

Cabot Oil and Gas Corporation (COG) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Cabot settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Robbins LLP Urges BBNX Stockholders Who Lost Money Investing in Beta Bionics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Beta Bionics, Inc. (NASDAQ: BBNX) common stock between July 30, 2025 and February 24, 2026, inclusive (the "Class Period"). Beta Bionics is a commercial-stage medical device company that offers an automated insulin delivery system for the treatment of diabetes, known as the iLet Bionic Pancreas insulin pump (...

Robbins LLP Urges HIMS Stockholders Who Lost Money Investing in Hims & Hers Health, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"). Hims operates a health and wellness platform that connects consumers to licensed healthcare professionals.The complaint alleges that Hims & Hers shared customers' protected health...

Robbins LLP Urges UNCY Stockholders Who Lost Money Investing in Unicycive Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of persons and entities who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026. Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies for the treatment of kidney diseases.The complaint alleges that Unicycive failed to properly inspect its t...
Back to Newsroom